We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Allergan plc | NYSE:AGN | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 193.02 | 0 | 01:00:00 |
By Josh Beckerman
Teva Pharmaceutical Industries Ltd., which is working toward a $40.5 billion acquisition of Allergan PLC's generics unit, increased its second-quarter earnings and revenue guidance on Tuesday.
Teva expects earnings excluding items of $1.19 to $1.22 a share, compared with a prior outlook of $1.16 to $1.20. The company expects revenue of $4.9 billion to $5 billion, compared with a May outlook of $4.7 billion to $4.9 billion.
In a conference call on Wednesday, Teva will provide preliminary guidance for the period through 2019 that includes results of the Allergan business.
Teva said in March that the deal announced last July would be completed later than expected as it works to obtain regulatory approval.
Analysts said the delay may have indicated a need for more asset sales to gain clearance.
The European Union approved the transaction in March, with conditions including a requirement that the companies divest the majority of Allergan's generics business in the U.K. and Ireland.
Last month, Impax Laboratories Inc. said it would buy a portfolio of generic drugs from Teva and Allergan for $586 million. Teva has also struck agreements for asset sales to Sagent Pharmaceuticals Inc. and Dr. Reddy's Laboratories.
Shares of Teva rose 1% to $53 after hours.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
July 12, 2016 18:49 ET (22:49 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Allergan Chart |
1 Month Allergan Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions